Sequential Checkpoint Inhibition in Pediatric Alveolar Soft Part Sarcoma: Durable Pembrolizumab Response After Atezolizumab Progression

Key Points

• The study aims to evaluate the effectiveness of sequential checkpoint inhibition therapies in pediatric patients with alveolar soft part sarcoma.
• Administered atezolizumab followed by pembrolizumab in pediatric patients
• Monitored patient responses to treatment
• Assessed progression of disease and treatment longevity
• Demonstrated durable pembrolizumab response in patients after progression on atezolizumab
• Highlighted significant tumor regression in treated individuals
• Indicated potential for sequential therapy to enhance treatment outcomes